|Symptoms||Short arms and legs, enlarged head, prominent forehead|
|Complications||Ear infections, hyperlordosis, back pain, spinal stenosis, hydrocephalus|
|Causes||Genetic (autosomal dominant mutation in the FGFR3 gene)|
|Risk factors||Paternal age|
|Diagnostic method||Based on symptoms, genetic testing if uncertain|
|Differential diagnosis||Hypochondroplasia, thanatophoric dysplasia, cartilage-hair hypoplasia, pseudoachondroplasia|
|Treatment||Support groups, growth hormone therapy, treatment of complications|
|Prognosis||10 year shorter life expectancy|
|Frequency||1 in 27,500 people|
In those with the condition, the arms and legs are short, while the torso is typically of normal length.
Those affected have an average adult height of 131 centimetres (4 ft 4 in) for males and 123 centimetres (4 ft) for females.
The disorder does not generally affect intelligence.
The disorder has an autosomal dominant mode of inheritance, meaning only one mutated copy of the gene is required for the condition to occur.
About 80% of cases result from a new mutation, which originates in the father's sperm.
The rest are inherited from a parent with the condition.
The risk of a new mutation increases with the age of the father.
In families with two affected parents, children who inherit both affected genes typically die before birth or in early infancy from breathing difficulties.
The condition is generally diagnosed based on the symptoms but may be confirmed by genetic testing.
Life expectancy of those affected is about 10 years less than average.
Achondroplasia is the most common cause of dwarfism and affects about 1 in 27,500 people.
The shortest known adult with the condition is Jyoti Amge, at 62.8 centimetres (2 ft 0.7 in).
Signs and symptoms
- Disproportionate dwarfism
- Shortening of the proximal limbs (called rhizomelic shortening)
- Short fingers and toes with trident hands
- Large head with prominent forehead frontal bossing
- Small midface with a flattened nasal bridge
- Spinal kyphosis (convex curvature) or lordosis (concave curvature)
- Varus (bowleg) or valgus (knock knee) deformities
- Frequent ear infections (due to Eustachian tube blockages), sleep apnea (which can be central or obstructive), and hydrocephalus
Achondroplasia is caused by a mutation in fibroblast growth factor receptor 3 (FGFR3) gene.
This gene is mainly responsible for making the protein, fibroblast growth factor receptor 3.
This protein contributes to the production of collagen and other structural components in tissues and bones.
When the FGFR3 gene is mutated it interferes with how this protein interacts with growth factors leading to complications with bone production.
Cartilage is not able to fully develop into bone, causing the individual to be disproportionately shorter in height.
In normal development FGFR3 has a negative regulatory effect on bone growth.
In achondroplasia, the mutated form of the receptor is constitutively active and this leads to severely shortened bones.
The effect is genetically dominant, with one mutant copy of the FGFR3 gene being sufficient to cause achondroplasia, while two copies of the mutant gene are invariably fatal (recessive lethal) before or shortly after birth (known as a lethal allele).
This occurs due to respiratory failure from an underdeveloped ribcage.
A person with achondroplasia thus has a 50% chance of passing dwarfism to each of their offspring.
People with achondroplasia can be born to parents that do not have the condition due to spontaneous mutation.
Achondroplasia can be inherited through autosomal dominance.
In couples where one partner has achondroplasia there is a 50% chance of passing the disorder onto their child every pregnancy.
In situations where both parents have achondroplasia there is a 50% chance the child will have achondroplasia, 25% chance the child will not, and a 25% chance that the child will inherit the gene from both parents resulting in double dominance and leading to severe or lethal bone dysplasia.
Studies have demonstrated that new gene mutations for achondroplasia are exclusively inherited from the father and occur during spermatogenesis; it has been theorized that sperm carrying the mutation in FGFR3 have a selective advantage over sperm with normal FGFR3.
The frequency of mutations in sperm leading to achondroplasia increase in proportion to paternal age, as well as in proportion to exposure to ionizing radiation.
The occurrence rate of achondroplasia in the children of fathers over 50 years of age is 1 in 1,875, compared to 1 in 15,000 in the general population.
Research by urologist Harry Fisch of the Male Reproductive Center at Columbia Presbyterian Hospital in 2013 indicated that in humans this defect may be exclusively inherited from the father and becomes increasingly probable with paternal age, specifically males reproducing after 35.
Clinical features include megalocephaly, short limbs, prominent forehead, thoracolumbar kyphosis and mid-face hypoplasia.
Complications like dental malocclusion, hydrocephalus and repeated otitis media can be observed.
The risk of death in infancy is increased due to the likelihood of compression of the spinal cord with or without upper airway obstruction.
A skeletal survey is useful to confirm the diagnosis of achondroplasia.
The skull is large, with a narrow foramen magnum, and relatively small skull base.
The vertebral bodies are short and flattened with relatively large intervertebral disk height, and there is congenitally narrowed spinal canal.
The iliac wings are small and squared, with a narrow sciatic notch and horizontal acetabular roof.
The tubular bones are short and thick with metaphyseal cupping and flaring and irregular growth plates.
Fibular overgrowth is present.
The ribs are short with cupped anterior ends.
If the radiographic features are not classic, a search for a different diagnosis should be entertained.
Because of the extremely deformed bone structure, people with achondroplasia are often "double jointed".
The trident hand configuration can be seen if the fingers are fully extended.
Another distinct characteristic of the syndrome is thoracolumbar gibbus in infancy.
There is no known cure for achondroplasia even though the cause of the mutation in the growth factor receptor has been found.
Although used by those without achondroplasia to aid in growth, human growth hormone does not help people with achondroplasia, which involve a different hormonal pathway.
Usually, the best results appear within the first and second year of therapy.
After the second year of growth hormone therapy, beneficial bone growth decreases, so the therapy is not a satisfactory long-term treatment.
An experimental drug called Vosoritide has shown promise in stage 3 human trials, although its long-term effects are unknown.
The controversial surgery of limb-lengthening will increase the length of the legs and arms of someone with achondroplasia.
Children with achondroplasia often have less muscle tone; because of this it is common for them to have delayed walking and motor skills.
It is also common for children to have bowed legs, scoliosis, lordosis, arthritis, issues with joint flexibility, breathing problems, ear infections, and crowded teeth.
These issues can be treated with surgery, braces, or physical therapy.
Hydrocephalus is a severe effect associated with achondroplasia in children.
This condition occurs when cerebrospinal fluid is not able to flow in and out of the skull because of how the spine narrows.
This fluid build up is associated with an enlarged head, vomiting, lethargy, headaches, and irritability.
A shunt surgery is commonly performed to treat this condition, but an endoscopic third ventriculostomy can also be done.
Adults with achondroplasia often face issues with obesity and sleep apnea.
It is also typical for adults to suffer from numbness or tingling in their legs because of nerve compression.
Pregnancy in women with achondroplasia is considered higher risk.
Women with achondroplasia generally have their babies delivered through C-sections to prevent complications that could occur with a natural birth.
Achondroplasia is one of several congenital conditions with similar presentations, such as osteogenesis imperfecta, multiple epiphyseal dysplasia tarda, achondrogenesis, osteopetrosis, and thanatophoric dysplasia.
This makes estimates of prevalence difficult, with changing and subjective diagnostic criteria over time.
One detailed and long-running study in the Netherlands found that the prevalence determined at birth was only 1.3 per 100,000 live births.
Another study at the same time found a rate of 1 per 10,000.
Based on their disproportionate dwarfism, some dog breeds traditionally have been classified as "achondroplastic".
Data from whole genome association studies in short-limbed dogs reveal a strong association of this trait with a retro-gene coding for fibroblast growth factor 4 (FGF4).
Therefore, it seems unlikely that dogs and humans are achondroplastic for the same reasons.
However, histological studies in some achondroplastic dog breeds have shown altered cell patterns in cartilage that are very similar to those observed in humans exhibiting achondroplasia.
A similar form of achondroplasia was found in a litter of piglets from a phenotypically normal Danish sow.
The dwarfism was inherited dominant in the offspring from this litter.
The piglets were born phenotypically normal, but became more and more symptomatic as they reached maturity.
This involved a mutation of the protein collagen, type X, alpha 1, encoded by the COL10A1 gene.
In humans a similar mutation (G595E) has been associated with Schmid metaphyseal chondrodysplasia (SMCD), a relatively mild skeletal disorder that is also associated with dwarfism.
The now-extinct Ancon sheep was created by humans through the selective breeding of common domestic sheep with achondroplasia.
The average-sized torso combined with the relatively smaller legs produced by achondroplasia was valued for making affected sheep less likely to escape without affecting the amount of wool or meat each sheep produced.
The drug inhibits the activity of FGFR3.
Credits to the contents of this page go to the authors of the corresponding Wikipedia page: en.wikipedia.org/wiki/Achondroplasia.